Fig. 6

Role of FGF7-FGFR2 signaling pathway and hypoxia in ovarian cancer progression. A Western blotting analysis of FGFR1-4 protein expression in OC cells treated with CAFs-CM. B Western blotting analysis of FGFR1-4 protein expression in OC cells treated with hFGF7 at concentrations of 10 ng/ml and 20 ng/ml. C Western blotting analysis of EMT marker protein expression in OC cells treated with CAFs-CM, FGF7-Ab, or FGFR2 antagonists. (D-E) Scatter plot illustrating the correlation between CAFs score from two algorithms and hypoxic pathway activation status. F Western blotting analysis of HIF-1α protein expression in OC cells treated with CAFs-CM, FGF7-Ab, or FGFR2 antagonists. G Schematic representation of HIF-1α protein ubiquitination. H Western blotting analysis of hydroxylated-HIF-1α and PHDs expression in OC cells treated with CAFs-CM or CAFs-CM pre-incubated with FGF7-Ab. I Co-immunoprecipitation of ubiquitin and pVHL with HIF1α in OC cells treated with CAFs-CM or CAFs-CM by preincubation with FGF7-Ab. J Western blotting analysis of HIF-1α protein expression in MG132-treated OC cells at different times. K Western blotting analysis of HIF-1α protein expression in OC cells treated with CAFs-CM or CAFs-CM pre-incubated with FGF7-Ab and MG132